MPNRF QUOTED IN CURE TODAY MAGAZINE
MPNRF | April 6, 2021
In an article published by CURE Today, MPN Research Foundation’s Executive Director, Michelle Woehrle, sat down with Kristie L. Kahl, to discuss the FDA’s approval of new Myelofibrosis drug Inrebic (fedratinib), the first approved drug for the disease in nearly a decade.
“We at the MPN Research Foundation are thrilled to see more options for people living with myelofibrosis who have long suffered with few options for relief,” Michelle Woehrle, executive director of the foundation, said in an interview with CURE. “We hope the approval of Inrebic ushers in a new era with many more new, safe and effective options for people living with polycythemia vera, essential thrombocythemia, and myelofibrosis.”